# Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

> **NCT02298283** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 40 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** Cyclophosphamide
- **DRUG:** Adriamycin
- **DRUG:** Oncovin
- **DRUG:** Bleomycin
- **DRUG:** Etoposide
- **DRUG:** Procarbazine
- **DRUG:** Prednisone
- **DRUG:** G-CSF
- **RADIATION:** 30 Grays

## Key facts

- **NCT ID:** NCT02298283
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-07-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298283, "Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02298283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*